Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising ...

I was living on the precipice of end-stage disease when I enrolled in the clinical trial that resulted in the historically fast Food and Drug Administration approval for the game-changing cystic ...

Getting your Trinity Audio player ready... Colorado’s new prescription drug review board decided in a first-in-the-nation vote that a medication costing more than $200,000 a year doesn’t qualify as ...

Cystic fibrosis investors came to learn a harsh lesson on August 10 about how concentrated a market can be: Sionna Therapeutics, Inc. (NASDAQ:SION) shares fell more than 90% following a key trial ...

Aug 10 (Reuters) - Sionna Therapeutics said on Monday it would stop developing its experimental drug as an addition to standard treatment for a type of genetic disorder after it failed to show a ...

Sionna Therapeutics (SION) downgraded to Hold after SION-719 Phase 2a failure; cash-rich but pipeline risk rises.

For people with cystic fibrosis, like Sabrina Walker, Trikafta has been a life-changer. Before she started taking the drug, she would wind up in the hospital for weeks at a time until antibiotics ...

COLORADO (KCNC) — Some Coloradans are sounding an alarm after learning a state board is considering capping the price of a life-saving drug. They’re worried the move could cause the manufacturer to ...

A cystic fibrosis drug called Trikafta is widely available in the U.S. and Europe. It has transformed life for tens of thousands of people with the disease in high-income countries. But what happens ...

When Seshagiri Buddana learned of a powerful new cystic fibrosis drug that was transforming lives in the United States and Europe, he was filled with hope that it could help his son, Hemanth, who had ...

Getting your Trinity Audio player ready... For people with cystic fibrosis, like Sabrina Walker, Trikafta has been a life-changer. Before the 37-year-old Erie mother started taking the drug, she would ...